FEIBA versus NovoSeven in hemophilia patients with inhibitors

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 7, 2013, Pages 772-778

  Franchini, Massimo ^a   Coppola, Antonio ^b   Tagliaferri, Annarita ^c   Lippi, Giuseppe ^d  

^a CARLO POMA HOSPITAL   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

Author keywords

alloantibodies; bleeding; bypassing agents; congenital hemophilia; FEIBA; inhibitors; NovoSeven

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; COMPARATIVE STUDY; COST; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HEMOPHILIA; HEMOPHILIA B; HEMOSTASIS; HUMAN; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOSIS; TREATMENT RESPONSE;

BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIIA; HEMOPHILIA A; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS;

EID: 84885028310     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0033-1354425     Document Type: Article

References (55)

1. Wight J., Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia: 2003; 9 4 418 435 (Pubitemid 36874391)
2. Lee C. A., Lillicrap D., Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Hemost: 2006; 32 02 10 14
3. Key N. S. Inhibitors in congenital coagulation disorders. Br J Haematol: 2004; 127 4 379 391 (Pubitemid 39539246)
4. Franchini M., Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost: 2009; 35 8 806 813
5. Franchini M., Mannucci P. M. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol: 2011; 72 4 553 562
6. Franchini M. The modern treatment of hemophilia: a narrative review. Blood Transfus: 2013; 11 2 178 182
7. Gringeri A., Mantovani L. G., Scalone L., Mannucci P. M. COCIS Study Group Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood: 2003; 102 7 2358 2363 (Pubitemid 37193570)
8. DiMichele D. M., Hoots W. K., Pipe S. W., Rivard G. E., Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia: 2007; 13 01 1 22 (Pubitemid 47009242)
9. Coppola A., Di Minno M. N., Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol: 2010; 150 5 515 528
10. Franchini M., Lippi G. Immune tolerance induction for patients with severe hemophilia A: a critical literature review. J Thromb Thrombolysis: 2011; 32 4 439 447
11. Gringeri A., Mannucci P. M. Italian Association of Haemophilia Centres Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia: 2005; 11 6 611 619 (Pubitemid 41631596)
12. Collins P. W., Chalmers E., Hart D. P., et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia (4th edition). Br J Haematol: 2013; 160 153 170
13. Astermark J., Rocino A., Von Depka M., et al. EHTSB Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia: 2007; 13 1 38 45 (Pubitemid 46002343)
14. Lloyd Jones M., Wight J., Paisley S., Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia: 2003; 9 4 464 520 (Pubitemid 36874393)
15. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost: 1999; 82 2 531 539
16. Franchini M., Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost: 2010; 36 5 485 492
17. Cromwell C., Aledort L. M. FEIBA: a prohemostatic agent. Semin Thromb Hemost: 2012; 38 3 265 267
18. Ehrlich H. J., Henzl M. J., Gomperts E. D. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia: 2002; 8 2 83 90 (Pubitemid 35238060)
19. Hilgartner M. W., Knatterud G. L. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood: 1983; 61 1 36 40 (Pubitemid 13169763)
20. Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost: 1997; 77 6 1113 1119 (Pubitemid 27311979)
21. Dimichele D., Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia: 2006; 12 4 352 362
22. Négrier C., Lienhart A., Numerof R., et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia: 2013; 19 3 e143 e150
23. Carcao M., Lambert T. Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia: 2010; 16 02 16 23
24. Valentino L. A. Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia: 2010; 16 2 263 271
25. Leissinger C., Gringeri A., Antmen B., et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med: 2011; 365 18 1684 1692
26. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost: 2008; 100 4 557 562
27. Hoffman M., Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost: 2012; 10 8 1478 1485
28. Hvid I., Rodriguez-Merchan E. C. Orthopaedic surgery in haemophilic patients with inhibitors: an overview. Haemophilia: 2002; 8 3 288 291 (Pubitemid 35277149)
29. Key N. S., Aledort L. M., Beardsley D., et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost: 1998; 80 6 912 918 (Pubitemid 28556692)
30. Levi M., Peters M., Büller H. R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med: 2005; 33 4 883 890
31. Kavakli K., Makris M., Zulfikar B., Erhardtsen E., Abrams Z. S., Kenet G. NovoSeven trial (F7HAEM-1510) investigators Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost: 2006; 95 4 600 605
32. Santagostino E., Mancuso M. E., Rocino A., Mancuso G., Scaraggi F., Mannucci P. M. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost: 2006; 4 2 367 371
33. Salaj P., Brabec P., Penka M., et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia: 2009; 15 3 752 759
34. Shapiro A. D. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol: 2008; 6 8 579 586
35. Kenet G., Martinowitz U. Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors. Semin Hematol: 2008; 45 2 01 S38 S41 (Pubitemid 351787683)
36. Abshire T., Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia: 2008; 14 5 898 902
37. Franchini M., Manzato F., Salvagno G. L., Montagnana M., Zaffanello M., Lippi G. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII. Semin Thromb Hemost: 2009; 35 8 814 819
38. Konkle B. A., Ebbesen L. S., Erhardtsen E., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost: 2007; 5 9 1904 1913 (Pubitemid 47288949)
39. Young G., Auerswald G., Jimenez-Yuste V., et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res: 2012; 130 6 864 870
40. Jiménez-Yuste V., Alvarez M. T., Martín-Salces M., et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia: 2009; 15 1 203 209
41. Santagostino E., Auerswald G., Jimenez-Yuste V., et al. European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH)-a prospective study. Haemophilia: 2010; 16 407
42. Abshire T. Safety update on recombinant factor VIIa in the treatment of congenital and acquired hemophilia. Semin Hematol: 2008; 45 2 01 S3 S6 (Pubitemid 351787678)
43. Aledort L. M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost: 2004; 2 10 1700 1708 (Pubitemid 40192708)
44. Knight C., Dano A. M., Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther: 2009; 26 1 68 88
45. Treur M. J., McCracken F., Heeg B., et al. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia: 2009; 15 2 420 436
46. Astermark J., Donfield S. M., DiMichele D. M., et al. FENOC Study Group A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood: 2007; 109 2 546 551 (Pubitemid 46105952)
47. Young G., Shafer F. E., Rojas P., Seremetis S. Single 270 micro g kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia: 2008; 14 2 287 294 (Pubitemid 351338689)
48. Iorio A., Matino D., D'Amico R., Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev: 2010; 8 8 CD004449
49. Lyseng-Williamson K. A., Plosker G. L. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. Pharmacoeconomics: 2007; 25 12 1007 1029 (Pubitemid 350208906)
50. Knight C., Dano A. M., Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia: 2009; 15 2 405 419
51. Hay J. W., Zhou Z. Y. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia: 2011; 17 5 e969 e974
52. Di Minno M. N., Di Minno G., Di Capua M., Cerbone A. M., Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia: 2010; 16 1 e190 e201
53. Salek S. Z., Benson G. M., Elezović I., et al. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia: 2011; 17 1 95 102
54. Ingerslev J., Sorensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol: 2011; 155 2 256 262
55. Gringeri A., Fischer K., Karafoulidou A., Klamroth R., López-Fernández M. F., Mancuso E. European Haemophilia Treatment Standardisation Board (EHTSB) Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia: 2011; 17 4 630 635